LT1001 clinical results accepted by the Clinical Journal of Pain

After successful execution of the license agreement with Syntano Technology Venture for China in June, Lumosa Therapeutics Co., Ltd. (TPEx 6535), receives a notification from “the Clinical Journal of Pain” (CJP) that the manuscript on LT1001 Phase III trial results was accepted for publication. “The Clinical Journal of Pain” is an esteemed international journal ranked among top 10 of clinical journals in analgesic and anesthetic field. It publishes many medical articles addressing pain management in clinical setting and new treatment models etc. for the past 30 years. The acceptance by CJP indicated LT1001 is regarded as an innovative product in clinical pain management, which deserves the recognition by international medical experts.

Lumosa recognized for its achievements at BioTaiwan

After successful licensing of LT1001 to Syntano Technology Venture, and approval for over-the-counter (OTC) listing (TPEx:6535) by the board of Taipei Exchange (TPEx), Lumosa was awarded the 2016 Biotech Potential Benchmark from the Bioindustry Association and Bronze Medal in the innovation category of 2016 Taipei Biotechnology Award from Taipei City Government. Dr. Wendy Huang, CEO of Lumosa Therapeutics, was also invited to give speeches in several conferences and seminars during the 2016 BioTaiwan event.

LT1001 out-licensed to China

Lumosa Therapeutics Co., Ltd. announced today the signing of an exclusive license agreement with Syntano Technology Venture - a Haike company (Syntano), granting Syntano the right to develop and commercialize its LT1001 product in China, Hong Kong and Macau.commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board. Please click link for more information

Lumosa appoints new BOD Chairman

Lumosa Therapeutics is delighted to announce the appointment of Dr. Chang-Hai Tsai as the new Chairman of its Board succeeding Dr. Rong-jin Lin. Dr. Tsai has been devoting his efforts in academic and research fields for over 30 years, accumulating extensive knowledge and expertise in biomedical area. He is currently one of the National Policy Advisors to the President, serves as the Chairman of the Board of China Medical University Hospital & China Medical University and is also the founding chairman of Asia University. Lumosa would like to convey its appreciation to Dr. Lin. His leadership, talent and experience have been a great asset to the company in his time as Chairman.

Dr. Wendy Huang, Lumosa CEO, speaks at Women's Day event

Lumosa Therapeutics was among the five technology based companies/woman organizations invited as an exhibitor in a Ministry of Health and Welfare-sponsored International Women’ s Day event held in NTU International Conference Center. The theme of this event was “Women in Today’s Technology”. Lumosa represent the Biotechnology community at this event. President Ma and officials from the Executive Yuan and the Ministry of Health and Welfare attended the event to show their support. Lumosa's CEO, Dr. Wendy Huang shared her thoughts with the event attendees; titled “ What Does It Take to be a Successful Bio-technology Lady?”

DC009 for the treatment of acute ischemic stroke was presented at 2016 ISC

Dr. Tun-Hsun Kuo of Lumosa Therapeutics presented a novel dual function molecule for the treatment of acute ischemic stroke on February 18, at the International Stroke Conference 2016, Los Angeles, USA. The therapeutic potential of DC009 was investigated by using a focal cerebral ischemia induced by arterial thrombosis model in aged mice (12-15 months old). DC009 showed a steady thrombolytic action and superior safety profile compared to vessel recanalization induced by rt-PA. Further, bleeding prolongation of DC009 (up to 30 mg/kg) in studies through tail amputation bleeding assay in mice was not observed; whereas rt-PA (10mg/kg) prolonged the bleeding to >10 folds of normal bleeding time. According to the MTD determined in preliminary toxicity dose range finding studies, safety margin greater than 50 folds was identified in both mouse and rat.